Brain tumor Glioma
Conditions
Interventions
Patients will receive 7 weeks of combined rTMS/sham + cognitive strategy
training (NRMP). 21 sessions of rTMS (3x times a week) and 7 weekly sessions of
cognitive strategy training will be given. Al
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - >= 18 years of age - Histological diagnosis of diffuse glioma (WHO grade 2,3, or 4) - Subjective cognitive impairment, defined as CFQ-score >= 44 - Stable disease, i.e. no oncological treatment for
Exclusion criteria
Exclusion criteria: - Current pregnancy or have given birth less than three months ago - Current other treatment for cognitive complaints - Karnofsky performance score
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of a combination therapy and study measurements in glioma patients. Feasibility will be assessed by completed intervention and measurements: how many of the included patients finish the intervention and obligatory measurements at T1. | — |
Secondary
| Measure | Time frame |
|---|---|
| A set of exploratory parameters will be used to investigate the feasibility of measurements aimed at assessing treatment effects in a future RCT. These parameters consist of EMA examining objective and subjective cognitive functioning along the whole study trajectory. Additionally, several measurements will be performed at baseline, directly after and six months after treatment, namely neuropsychological assessments, questionnaires for subjective cognitive functioning, questionnaires concerning quality of life, functioning, fatigue, and psychological wellbeing, neurological examination, advanced neuroimaging and clinical parameters (tumor location, undergone previous treatments, medication use) will be assessed. Additionally, tolerability and side-effects of the rTMS treatment will be assessed. | — |
Countries
Netherlands
Outcome results
None listed